Stanley Druckenmiller Put 18% of His $3.4 Billion Portfolio in This One Stock. Is Natera a Buy?

Stanley Druckenmiller Put 18% of His $3.4 Billion Portfolio in This One Stock. Is Natera a Buy?

Brett Schafer, The Motley Fool

Tue, August 4, 2026 at 7:05 PM GMT+3 3 min read

• NTRA +1.66%
• NVDA +1.71%

It can pay to track what the big investors on Wall Street are trading in quarterly 13-F filings. This quarter, legendary hedge fund manager Stanley Druckenmiller added to his largest stock position, buying more Natera (NASDAQ: NTRA) for his family office. The innovative genetic testing company now accounts for 18% of Druckenmiller's 13-F portfolio, which includes all his U.S.-listed stocks.

Should you follow Druckenmiller into Natera stock? Let's take a closer look at the numbers and find out.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

Advances in DNA testing

Modern medicines and treatments have led to a growing demand for advanced patient diagnostics. To tailor medicines for patients in prenatal care or with cancer, you need to understand more about their bodies and specific genetic makeup.

Natera specializes in bridging the gap between doctors and patients, using innovative cell-free DNA testing to help diagnose outcomes. Specifically, it serves the prenatal and cancer testing markets. For pregnant patients, a doctor can use a Natera test to diagnose any problems with the fetus, all with minimal physical intervention. Its cancer testing has a variety of use cases, but an important one is checking for residual disease evidence in patients, which can be invaluable for someone dealing with cancer in remission.

This market is growing like a weed, and Natera is leading the way with its best-in-class testing innovations and patent protections. It has also recently made strides in a new pillar of its business: organ donor testing, which evaluates how well a new organ functions after transplantation.

Total revenue grew 39% year over year last quarter and is up 1,000% over the last 10 years. It is this growth inflection -- and the prospects for continued tailwinds in the sector -- that led Druckenmiller to make Natera his largest stock position.

Is Natera stock a buy?

While Natera has been a nice winner for Druckenmiller over the last few years, the stock is up almost 100% over the last 12 months, driven by solid revenue growth. Is it still a buy today?

Right now, Natera trades at an expensive-looking price-to-sales (P/S) ratio of 15, which is significantly higher than the stock market average in the United States. Investors like Druckenmiller are quite optimistic about this business's growth prospects.

We cannot value the business on earnings, since it has not generated a net profit in the last few years. However, it does have very high gross margins -- 65% last quarter -- that indicate the business will have strong bottom-line margins at greater maturity.

This means investors could earn strong long-term returns by owning Natera stock, but they should only buy if they believe this durable revenue growth will continue in the years ahead.

Should you buy stock in Natera right now?

Before you buy stock in Natera, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Natera wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $395,463!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,268,290!*

Now, it's worth noting Stock Advisor's total average return is 927% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of August 4, 2026.

Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Natera. The Motley Fool has a disclosure policy.

Stanley Druckenmiller Put 18% of His $3.4 Billion Portfolio in This One Stock. Is Natera a Buy? was originally published by The Motley Fool